SARS-CoV-2 mRNA vaccination (COVID-19 vaccination) within 100 days of immune checkpoint inhibitor (ICI) treatment was reported to improve survival and prevent disease progression in patients with non-small cell lung cancer (NSCLC) and metastatic melanoma (Grippin et al., Nature, 2025). However, the clinical evidence, derived from real-world observational data, suffers from methodological limitations. Specifically, the vaccinated and unvaccinated groups differed in…
Re-evaluating the effect of SARS-CoV-2 mRNA vaccination on clinical outcomes in patients treated with immune checkpoint inhibitors
medRxiv Oncology | | Dumas, E., Gougis, P., Gasparollo, L., Spano, J.-P., Stensrud, M. J.
Topics: lung-cancer, skin-cancer, blood-cancer, cervical-cancer, immunotherapy